Ribavirin: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Jamie Costa (talk | contribs) No edit summary |
Jamie Costa (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide <ref name="gish">DOI: 10.1093/jac/dki405 </ref> | 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide <ref name="gish">DOI: 10.1093/jac/dki405 </ref> | ||
<StructureSection load='' size='340' side='right' caption=' | <StructureSection load='' size='340' side='right' caption='Ribavirin [[4PB1]]' scene='74/746008/Ribavirin_atalla/1'> | ||
<scene name='74/746008/Ribavirin_atalla/1'>TextToBeDisplayed</scene> | <scene name='74/746008/Ribavirin_atalla/1'>TextToBeDisplayed</scene> | ||
== Overview == | == Overview == | ||
Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients, but since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C. The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b <ref name="gish"/>DOI: 10.1093/jac/dki405 <ref>. | Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients, but since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C. The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b <ref name="gish"/>DOI: 10.1093/jac/dki405 </ref>. | ||
== Structure & Function == | == Structure & Function == | ||
